bioRxiv · 10.1101/2025.04.17.649341
Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors
Abstract
Selectivity for closely related isoforms of protein kinases is a major challenge in the design of drugs and chemical probes. Covalent targeting of unique cysteines is a potential strategy to achieve selectivity for highly conserved binding sites. Here, we used a pan-LIMK inhibitor to selectively probe LIMK1 over LIMK2 by targeting the LIMK1-specific cysteine C349 located in the glycine-rich loop region. Binding kinetics of both non-covalent and covalent LIMK inhibitors were investigated, and the fast on-rate and small size of type-I inhibitors were used in the design of a covalent LIMK1 inhibitor. The developed cell-active, isoform-selective LIMK1 inhibitor showed excellent proteome-wide selectivity in pull-down assays, enabling studies of LIMK1 isoform-selective functions in cellular model systems and providing a versatile chemical tool for studies of the LIMK signalling pathway.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Mandel, S., Hanke, T., Prendiville, N., Baena-Nuevo, M., Berger, L. M., Farges, F., Schwalm, M. P., Berger, B. T., Kraemer, A., Elson, L., Saraswati, H., Azeez, K. R. A., Dederer, V., Mathea, S., Corrionero, A., Alfonso, P., Keller, S., Gstaiger, M., Krause, D. S., Mueller, S., Roehm, S., Knapp, S.. 2025-04-19. Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors. https://doi.org/10.1101/2025.04.17.649341
Cite the original work for its findings. Save a collection to share your selection of sources.